AstraZeneca To Acquire Lung Cancer Drug License For $1.5B
Multinational pharma giant AstraZeneca said Tuesday that it has agreed to acquire worldwide rights to develop and commercialize a lung cancer drug for as much as $1.5 billion from Chinese pharma...To view the full article, register now.
Already a subscriber? Click here to view full article